Organization (Other)
Humanitas Clinical and Research Center
ClinicalTrials.gov lists Humanitas Clinical and Research Center as lead sponsor of 33 trials. It has 15 active development programs and 7 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.8 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Humanitas Clinical and Research Center: 33 lead-sponsored trials and 0 legal-entity registrations.
Disease areas (40)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Carcinoma, Hepatocellular | 6 |
| Liver Neoplasms | 6 |
| Critical Illness | 4 |
| Inflammation | 3 |
| Sepsis | 3 |
Showing 5 of 40 disease areas.
Trials by start year as sponsor or collaborator (11)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2025 | 3 |
| 2024 | 2 |
| 2023 | 4 |
| 2022 | 3 |
| 2021 | 7 |
| 2020 | 6 |
| 2019 | 8 |
| 2018 | 1 |
| 2015 | 2 |
| 2010 | 1 |
Showing 10 of 11 years.
Recruitment duration, a model prediction: none of the 33 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (15)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| BENRALIZUMAB | Nasal Polyps | Phase 3 | 1 |
| Cannabidiol and β-Caryophyllene Patch | Pain | Phase 3 | 1 |
| Cannabidiol and β-Caryophyllene Patch | Neck Pain | Phase 3 | 1 |
| 10 cc of oxygen-ozone plus thumb splint | Osteoarthritis | Phase 3 | 1 |
| BENRALIZUMAB | Polyps | Phase 3 | 1 |
Showing 5 of 15 active programs.
Approved assets (7)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Intravenous midazolam (3 mg initially, with optional 3 mg boluses) plus fentanyl (100 mcg) for procedural sedation. | 1 |
| Intravenous remimazolam (5 mg initially, with optional 2.5 mg boluses) plus fentanyl (100 mcg) for procedural sedation. | 1 |
| HYALURONIC ACID | 1 |
| BENRALIZUMAB | 1 |
| VEDOLIZUMAB | 1 |
Showing 5 of 7 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 50% hit target (n=6) | 17% on time (n=6) |
Journals published in (79)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Anesthesiology | 6 |
| Lancet (London, England) | 5 |
| Critical care (London, England) | 4 |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 4 |
| Nature | 4 |
Showing 5 of 79 journals.
Organization relationships (5)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Regina Elena Cancer Institute | Co sponsors trial with | 1 |
| Research Institute Against Digestive Cancer IRCAD | Co sponsors trial with | 1 |
| Treviso Regional Hospital | Co sponsors trial with | 1 |
| Universita di Verona | Co sponsors trial with | 1 |
| San Gerardo Hospital | Co sponsors trial with | 1 |
Latest dated events (38)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2025-09-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-08-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-01-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2024-11-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2024-02-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 38 events.
Biomarker capability evidence (25)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
| ERBB2 | Trial collaborator | Named in trial inclusion criteria |
| SH2D1A | Trial sponsor | Named in trial inclusion criteria |
| TICAM2 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 25 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.